Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Clinical trial NCT06980116 · RECRUITING

Trial details

NCT number: NCT06980116
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed or Refractory B-cell Malignancies Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Follicular Lymphoma (FL)Marginal Zone Lymphoma (MZL)Mantle Cell Lymphoma (MCL)Diffuse-large B-cell Lymphoma (DLBCL)Waldenstrom's Macroglobulinemia (WM)

Start date: 2025-03-31
Primary completion: 2028-06-01
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.